Net unrealized gains (losses) on securities still held
Regeneron Pharmaceuticals Net unrealized gains (losses) on securities still held decreased by 1026.8% to -$65.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 272.7%, from $38.10M to -$65.80M. Over 2 years (FY 2021 to FY 2025), Net unrealized gains (losses) on securities still held shows an upward trend with a 21.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase reflects positive market performance of the company's investment portfolio, potentially signaling latent liquidity.
Detailed definition
The change in the fair value of investment securities held by the company that are classified as available-for-sale or s...
Peer comparison
Standard for companies with significant cash reserves invested in marketable securities.
other_other_comprehensive_income_unrealized_holding_gain_503fecHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$800.00K | -$6.40M | -$35.90M | -$144.90M | -$53.70M | -$51.30M | $57.20M | -$15.70M | $21.30M | $95.40M | $3.50M | $7.90M | $128.20M | $38.10M | $22.10M | $15.70M | $7.10M | -$65.80M |
| QoQ Change | — | -700.0% | -460.9% | -303.6% | +62.9% | +4.5% | +211.5% | -127.4% | +235.7% | +347.9% | -96.3% | +125.7% | >999% | -70.3% | -42.0% | -29.0% | -54.8% | <-999% |
| YoY Change | — | — | — | — | <-999% | -701.6% | +139.5% | +70.8% | +141.5% | — | -93.9% | +150.3% | +501.9% | +988.6% | +179.7% | -87.8% | — | -272.7% |
Net unrealized gains (losses) on securities still held at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's net unrealized gains (losses) on securities still held?
- Regeneron Pharmaceuticals (REGN) reported net unrealized gains (losses) on securities still held of -$65.80M in Q1 2026.
- How has Regeneron Pharmaceuticals's net unrealized gains (losses) on securities still held changed year-over-year?
- Regeneron Pharmaceuticals's net unrealized gains (losses) on securities still held decreased by 272.7% year-over-year, from $38.10M to -$65.80M.
- What is the long-term trend for Regeneron Pharmaceuticals's net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), Regeneron Pharmaceuticals's net unrealized gains (losses) on securities still held has grown at a 21.3% compound annual growth rate (CAGR), from -$56.40M to $83.00M.
- What does net unrealized gains (losses) on securities still held mean?
- The change in value of investment holdings that have not yet been sold.